Technical Analysis for AZNCF - Astrazeneca Plc Ord
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
85.61 | 0.53% | 0.4545 |
AZNCF closed up 0.53 percent on Monday, September 16, 2019, on 8 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| See historical AZNCF trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Strong but Oversold | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.53% | |
| Gapped Down | Weakness | 0.53% | |
| Fell Below 20 DMA | Bearish | -0.11% | |
| MACD Bearish Signal Line Cross | Bearish | -0.11% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Chemistry Cancer Chemical Compounds Organic Compounds Neuroscience Metabolic Diseases Cardiovascular Diseases Respiratory Diseases Chloroarenes Astrazeneca Bristol Myers Squibb Gastrointestinal Diseases
Chemistry Cancer Chemical Compounds Organic Compounds Neuroscience Metabolic Diseases Cardiovascular Diseases Respiratory Diseases Chloroarenes Astrazeneca Bristol Myers Squibb Gastrointestinal Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
| Date | Title |
|---|
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 90.59 |
| 52 Week Low | 56.2 |
| Average Volume | 3,659 |
| 200-Day Moving Average | 75.6691 |
| 50-Day Moving Average | 82.271 |
| 20-Day Moving Average | 87.0103 |
| 10-Day Moving Average | 88.1303 |
| Average True Range | 1.4416 |
| ADX | 16.12 |
| +DI | 42.9897 |
| -DI | 49.3303 |
| Chandelier Exit (Long, 3 ATRs ) | 86.2652 |
| Chandelier Exit (Short, 3 ATRs ) | 84.0748 |
| Upper Bollinger Band | 92.4848 |
| Lower Bollinger Band | 81.5358 |
| Percent B (%b) | 0.37 |
| BandWidth | 12.583568 |
| MACD Line | 1.3547 |
| MACD Signal Line | 1.9375 |
| MACD Histogram | -0.5828 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 86.3188 | ||||
| Resistance 3 (R3) | 86.2400 | 85.9250 | 86.2006 | ||
| Resistance 2 (R2) | 85.9250 | 85.7445 | 85.9644 | 86.1612 | |
| Resistance 1 (R1) | 85.7675 | 85.6330 | 85.8463 | 85.8463 | 86.1219 |
| Pivot Point | 85.4525 | 85.4525 | 85.4919 | 85.4919 | 85.4525 |
| Support 1 (S1) | 85.2950 | 85.2720 | 85.3738 | 85.3738 | 85.0981 |
| Support 2 (S2) | 84.9800 | 85.1605 | 85.0194 | 85.0588 | |
| Support 3 (S3) | 84.8225 | 84.9800 | 85.0194 | ||
| Support 4 (S4) | 84.9013 |
